Bigelow, Douglas

Bigelow, Douglas, a for-profit sole proprietorship based in Media, Pennsylvania, provides medical expert case review services exclusively to the Department of Health and Human Services' Health Resources and Services Administration (HRSA) for the Vaccine Injury Compensation Program (VICP) as a prime contractor under small-business set-aside BPA call orders. The vendor operates under PSC code Support-Professional: Expert Witness and carries primary NAICS classification 6111 (Offices of Physicians), reflecting its specialization in vaccine-injury medical assessment and expert testimony for VICP compensability determinations.

Bigelow, Douglas maintains 100% customer concentration with HRSA, holding all 77 awards exclusively under VICP-related BPA vehicles. The vendor sits on four active blanket purchase agreements: a $7.5 million single-award BPA established July 19, 2024 and running through July 18, 2029 (the primary vehicle for forward work), a $249,999 multiple-award BPA (HHSH250201400005B) with 34 task orders totaling $108 thousand in combined potential value, and two legacy multiple-award vehicles (75R60219A00086 and HHSH250201200003B) carrying the balance of recent call orders. Individual BPA call task orders typically range from $600 to $24,375 in ceiling value and carry firm fixed-price terms. Most recent work includes a $24,375 small-business-set-aside BPA call awarded August 25, 2026 with ultimate completion July 24, 2027, an $11,250 call awarded April 13, 2026 (completion March 12, 2027), and a $7,500 call from June 7, 2024.

Award activity peaked in 2021 with eleven call orders but has contracted to three awards in 2024 and two in 2026, reflecting either seasonal or program-cycle variation rather than a sustained decline. Only two awards (combined potential value $36 thousand) complete within the next twenty-four months, suggesting minimal near-term recompete exposure. Across its entire footprint, the vendor has obligated only $269 thousand against $8.3 million in combined potential value (3% obligation rate), consistent with the per-order ceiling pattern and task-order-based contract execution. The vendor has maintained continuous VICP work since at least 2012, establishing a specialized domain position in vaccine-injury medical determination within a narrow federal customer base.